



Express Mail No.: EV473971020US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Dingivan, Christine A.

Confirmation No.: 7146

Application No.: 10/091,313

Group Art Unit: 1644

Filed: March 4, 2002

Examiner: Skelding, Zachary S.

For: METHODS OF PREVENTING OR
TREATING INFLAMMATORY OR
AUTOIMMUNE DISORDERS BY
ADMINISTERING CD2 BINDING
MOLECULES IN COMBINATION WITH
ANTI-ANGIOGENIC AGENTS (as
amended)

Attorney Docket No.: 10271-063-999

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.56 AND §1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 and §1.97 to inform the United States Patent and Trademark Office ("USPTO") of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicant hereby invite the Examiner's attention to references A78-A80, B24 and C152-C158 listed on the attached form entitled "List of References Cited by Applicant."

Copies of references B24 and C152-C158 are submitted herewith. Copies of references A78-A80 are not submitted herewith because they are U.S. patent application publications. Pursuant to 37 C.F.R. § 1.98 (a)(2)(i) as amended (*see* Fed. Reg. vol. 69, no. 182, Sept. 21, 2004), the requirement for providing a copy of each U.S. patent or U.S. patent application publication listed in an Information Disclosure Statement in a patent application, regardless of the filing date of the application, is eliminated.

Identification of the listed reference is not meant to be construed as an admission of Applicant or Attorneys for Applicant that such reference is available as "prior art" against the subject application.

Applicant respectfully requests that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. §1.97(b), since this information disclosure statement is being filed after the mailing date of a first Office Action on the merits, a fee of \$180 is believed to be due in connection herewith. Please charge the required fee to Jones Day deposit account no. 50-3013. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Date: March 12, 2007

Anthony M. Inogna 35,203
Anthony M. Inogna (Reg. No.)

By: Jennifer J. Chheda 46,617
Jennifer J. Chheda (Reg. No.)

JONES DAY
222 East 41st Street
New York, NY 10017
(212) 326-3939

Enclosures



LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.
10271-063-999

APPLICATION NO.
10/091,313

APPLICANT
Dingivan

FILING DATE
March 4, 2002

ART UNIT
1644

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A78	2003/0185824	10/02/03	Vaishnaw et al.	
	A79	2004/0170635	09/02/04	Vaishnaw et al.	
	A80	2004/0265305	12/30/04	Vaishnaw et al.	

FOREIGN PATENT DOCUMENTS

		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T
	B24	WO 02/060480	08/08/02	Biogen, Inc.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C152	BIMALANGSHU et al., 2005, "Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogenic stem cell transplantation," Br. J. Haematol. 128:351-359	
	C153	KOENECKE et al., 2003, "NK cell recovery, chimerism, function, and recognition in recipients of haploidentical hematopoietic cell transplantation following nonmyeloablative conditioning using a humanized anti-CD2 mAb, Medi-507," Exp. Hematol. 31(10):911-23	
	C154	SHAFFER et al., 2005, "Fludarabine treatment is associated with depletion of host CD4+CD25^{HIGH}, FOXP3+, CTLA-4+ cells and increased incidences of full donor chimerism and GVHD in non-myeloablative haploidentical hematopoietic cell transplant recipients," 47th Annual Meeting of the American Society of Hematology, Abstract, 2898	
	C155	SPITZER et al., 2003, "Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies," Transplantation 75(10):1748-51	
	C156	SPITZER et al., 2005, "In vivo and ex vivo T-cell depleted (TCD) nonmyeloablative haploidentical stem cell transplantation (NSCT) for hematologic malignancy (HM)," 47th Annual Meeting of the American Society of Hematology, Abstract, 4731	
	C157	VILLARD et al., 2006, "High percentage of CD4+CD25high expressing FOXP3 and CTLA4 characterized recipient of haploidentical hematopoietic cell transplantation with low T cell recovery," Annual Meeting of the Swiss Society for Allergology and Immunology, Abstract, S33	
	C158	YEE et al., 2005, "Minimal HLA disparity and KIR ligand compatibility in host versus graft direction may facilitate donor engraftment following in vivo and ex vivo T cell depleted (TCD) nonmyeloablative haploidentical stem cell transplantation for hematologic malignancies," 47th Annual Meeting of the American Society of Hematology, Abstract, 3668	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.